Key Points
- Insider buying: Enovis insider Oliver Engert bought 1,000 shares on March 3 at $24.77, bringing his direct stake to 44,640 shares; he also purchased 1,000 shares on Feb. 27 and 250 shares on Mar. 4 for a total of 2,250 recent shares bought.
- Recent results and guidance: Enovis reported Q results with a $0.95 EPS (vs. $0.81 consensus) and $575.8M revenue (slightly below the $584.3M estimate), and set FY2026 guidance of $3.520–$3.730 EPS.
- Market view: The stock trades near $24.36 with a $1.39B market cap and a 12‑month range of $21.00–$40.69, while analysts hold a consensus rating of Moderate Buy and an average price target of $47.43.
Enovis Corporation (NYSE:ENOV - Get Free Report) insider Oliver Engert bought 1,000 shares of Enovis stock in a transaction dated Tuesday, March 3rd. The shares were bought at an average cost of $24.77 per share, with a total value of $24,770.00. Following the completion of the transaction, the insider directly owned 44,640 shares in the company, valued at approximately $1,105,732.80. This trade represents a 2.29% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.
Oliver Engert also recently made the following trade(s):
- On Wednesday, March 4th, Oliver Engert purchased 250 shares of Enovis stock. The stock was bought at an average cost of $25.10 per share, for a total transaction of $6,275.00.
- On Friday, February 27th, Oliver Engert acquired 1,000 shares of Enovis stock. The shares were purchased at an average cost of $25.50 per share, with a total value of $25,500.00.
Enovis Stock Performance
NYSE:ENOV traded up $0.04 during trading hours on Friday, reaching $24.36. The stock had a trading volume of 494,599 shares, compared to its average volume of 1,144,044. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.02. The stock has a 50 day simple moving average of $24.15 and a 200 day simple moving average of $28.08. Enovis Corporation has a 12-month low of $21.00 and a 12-month high of $40.69. The stock has a market cap of $1.39 billion, a P/E ratio of -1.18 and a beta of 1.46.
Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.95 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.14. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.The company had revenue of $575.76 million during the quarter, compared to the consensus estimate of $584.30 million. During the same quarter in the prior year, the company earned $0.98 EPS. The firm's quarterly revenue was up 2.6% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, research analysts forecast that Enovis Corporation will post 2.79 EPS for the current fiscal year.
Hedge Funds Weigh In On Enovis
A number of institutional investors and hedge funds have recently modified their holdings of the company. River Road Asset Management LLC raised its stake in Enovis by 3.2% in the fourth quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company's stock valued at $39,621,000 after buying an additional 46,289 shares in the last quarter. Corient Private Wealth LLC increased its stake in Enovis by 540.7% in the fourth quarter. Corient Private Wealth LLC now owns 55,180 shares of the company's stock valued at $1,470,000 after purchasing an additional 46,568 shares during the last quarter. Front Street Capital Management Inc. lifted its position in shares of Enovis by 75.8% during the 4th quarter. Front Street Capital Management Inc. now owns 361,932 shares of the company's stock worth $9,642,000 after buying an additional 156,069 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Enovis in the 4th quarter valued at $561,000. Finally, Susquehanna Portfolio Strategies LLC raised its stake in Enovis by 249.9% during the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 140,997 shares of the company's stock worth $3,756,000 after acquiring an additional 100,704 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company's stock.
Analyst Upgrades and Downgrades
ENOV has been the topic of a number of analyst reports. Zacks Research raised shares of Enovis from a "hold" rating to a "strong-buy" rating in a report on Wednesday. Canaccord Genuity Group dropped their price objective on Enovis from $58.00 to $50.00 and set a "buy" rating on the stock in a report on Wednesday, December 17th. Wells Fargo & Company upped their price target on Enovis from $41.00 to $42.00 and gave the company an "overweight" rating in a research report on Friday, November 7th. Evercore reaffirmed an "outperform" rating on shares of Enovis in a research note on Monday, January 12th. Finally, Needham & Company LLC increased their target price on shares of Enovis from $49.00 to $52.00 and gave the stock a "buy" rating in a research note on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Enovis has a consensus rating of "Moderate Buy" and an average price target of $47.43.
Get Our Latest Stock Analysis on Enovis
Enovis Company Profile
(
Get Free Report)
Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.
The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
